1-5 of 5
Nancy E. Kohl
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P249: Preclinical antitumor activity of NVL-520 in patient-derived models harboring ROS1 fusions, including G2032R solvent front mutation

Amit M. Deshpande, Satoshi Yoda, Anupong Tangpeerachaikul, Nancy E. Kohl, Joshua C. Horan, Aaron N. Hata, Henry E. Pelish
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P249.
https://doi.org/10.1158/1535-7163.TARG-21-P249
Published: 01 December 2021
View article titled, Abstract P249: Preclinical antitumor activity of NVL-520 in patient-derived models harboring ROS1 fusions, including G2032R solvent front mutation
Journal Articles

Abstract P244: NVL-655 exhibits antitumor activity in lorlatinib-resistant and intracranial models of ALK-rearranged NSCLC

Anupong Tangpeerachaikul, Amit Deshpande, Nancy E. Kohl, Joshua C. Horan, Henry E. Pelish
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P244.
https://doi.org/10.1158/1535-7163.TARG-21-P244
Published: 01 December 2021
View article titled, Abstract P244: NVL-655 exhibits antitumor activity in lorlatinib-resistant and intracranial models of ALK-rearranged NSCLC
Journal Articles

Abstract C036: Discovery of IACS-13909, an allosteric SHP2 inhibitor that overcomes multiple mechanisms underlying osimertinib resistance

Yuting Sun, Brooke A Meyers, Sarah B Johnson, Angela L Harris, Barbara Czako, Jason B Cross, Paul G Leonard, Faika Mseeh, Maria E Di Francesco, Connor A Parker, Qi Wu, Christopher A Bristow, Jason P Burke, Caroline C Carrillo, Christopher L Carroll, Qing Chang, Ningping Feng, Sonal Gera, Gao Guang, Justin Kwang-Lay Huang, Yongying Jiang, Zhijun Kang, Jeffrey J Kovacs, Xiaoyan Ma, Pijus K Mandal, Timothy McAfoos, Robert A Mullinax, Michael D Peoples, Vandhana Ramamoorthy, Sahil Seth, Erika Suzuki, Christopher Conrad Williams, Simon S Yu, Andy M Zuniga, Giulio F Draetta, Joseph R Marszalek, Timothy P Heffernan, Nancy E Kohl, Philip Jones
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): C036.
https://doi.org/10.1158/1535-7163.TARG-19-C036
Published: 01 December 2019
View article titled, Abstract C036: Discovery of IACS-13909, an allosteric SHP2 inhibitor that overcomes multiple mechanisms underlying osimertinib resistance
Journal Articles

Identification of biomarkers for tumor endothelial cell proliferation through gene expression profiling

James S. Hardwick, Yi Yang, Chunsheng Zhang, Bin Shi, Rosemary McFall, Elizabeth J. Koury, Susan L. Hill, Hongyue Dai, Robert Wasserman, Robert L. Phillips, Edward J. Weinstein, Nancy E. Kohl, Michael E. Severino, John R. Lamb, Laura Sepp-Lorenzino
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2005) 4 (3): 413–425.
https://doi.org/10.1158/1535-7163.MCT-04-0209
Published: 14 March 2005
View article titled, Identification of biomarkers for tumor endothelial cell proliferation through gene expression profiling
Open the PDF for Identification of biomarkers for tumor endothelial cell proliferation through gene expression profiling in another window
Includes: Supplementary data
Journal Articles

Preclinical and Clinical Pharmacodynamic Assessment of L-778,123, a Dual Inhibitor of Farnesyl:Protein Transferase and Geranylgeranyl:Protein Transferase Type-I

Robert B. Lobell, Dongming Liu, Carolyn A. Buser, Joseph P. Davide, Elizabeth DePuy, Kelly Hamilton, Kenneth S. Koblan, Yih Lee, Scott Mosser, Sherri L. Motzel, James L. Abbruzzese, Charles S. Fuchs, Eric K. Rowinsky, Eric H. Rubin, Sunil Sharma, Paul J. Deutsch, Kathryn E. Mazina, Briggs W. Morrison, Lynne Wildonger, Siu-Long Yao, Nancy E. Kohl
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2002) 1 (9): 747–758.
Published: 01 July 2002
View article titled, Preclinical and Clinical Pharmacodynamic Assessment of L-778,123, a Dual Inhibitor of Farnesyl:Protein Transferase and Geranylgeranyl:Protein Transferase Type-I
Open the PDF for Preclinical and Clinical Pharmacodynamic Assessment of L-778,123, a Dual Inhibitor of Farnesyl:Protein Transferase and Geranylgeranyl:Protein Transferase Type-I in another window